Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Risk of heart failure in type 2 diabetes complicated by incident ischaemic heart disease and end-stage renal disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Mechanical respiratory support in cardiogenic shock: reply

    Research output: Contribution to journalComment/debateResearchpeer-review

  3. Pulmonary artery pulsatility index: physiological basis and clinical application

    Research output: Contribution to journalReviewResearchpeer-review

  1. Smartphone Activation of Citizen Responders to Facilitate Defibrillation in Out-of-Hospital Cardiac Arrest

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Age-specific trends in incidence and survival of out-of-hospital cardiac arrest from presumed cardiac cause in Denmark 2002-2014

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Early and late risk of ischemic stroke after TAVR as compared to a nationwide background population

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Valve regurgitation in patients surviving endocarditis and the subsequent risk of heart failure

    Research output: Contribution to journalJournal articleResearchpeer-review

  • DAPA-HF Committees and Investigators
View graph of relations

BACKGROUND: Sodium-glucose co-transporter 2 (SGLT2) inhibitors have been shown to reduce the risk of incident heart failure hospitalization in individuals with type 2 diabetes who have, or are at high risk of, cardiovascular disease. Most patients in these trials did not have heart failure at baseline and the effect of SGLT2 inhibitors on outcomes in individuals with established heart failure (with or without diabetes) is unknown.

DESIGN AND METHODS: The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure trial (DAPA-HF) is an international, multicentre, parallel group, randomized, double-blind, study in patients with chronic heart failure, evaluating the effect of dapagliflozin 10 mg, compared with placebo, given once daily, in addition to standard care, on the primary composite outcome of a worsening heart failure event (hospitalization or equivalent event, i.e. an urgent heart failure visit) or cardiovascular death. Patients with and without diabetes are eligible and must have a left ventricular ejection fraction ≤ 40%, a moderately elevated N-terminal pro B-type natriuretic peptide level, and an estimated glomerular filtration rate ≥ 30 mL/min/1.73 m2 . The trial is event-driven, with a target of 844 primary outcomes. Secondary outcomes include the composite of total heart failure hospitalizations (including repeat episodes), and cardiovascular death and patient-reported outcomes. A total of 4744 patients have been randomized.

CONCLUSIONS: DAPA-HF will determine the efficacy and safety of the SGLT2 inhibitor dapagliflozin, added to conventional therapy, in a broad spectrum of patients with heart failure and reduced ejection fraction.

Original languageEnglish
JournalEuropean Journal of Heart Failure
Volume21
Issue number5
Pages (from-to)665-675
Number of pages11
ISSN1388-9842
DOIs
Publication statusPublished - 1 May 2019

    Research areas

  • Clinical trial, Heart failure, Sodium–glucose co-transporter 2 inhibitor, Type 2 diabetes mellitus

ID: 58080084